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OBJECTIVE— To optimize identification of future diabetic patients, the American Diabetes
Association (ADA) introduced criteria for impaired fasting glucose (IFG) in 1997 (IFG 6.1
mmol/l [IFG6.1]) and lowered the threshold from 6.1 to 5.6 mmol/l (IFG5.6) in 2003. Our aim
was to assess the consequences of lowering the IFG cutoff on the risk of cardiovascular disease
(CVD) mortality and to evaluate whether this risk is explained by a conversion to type 2 diabetes
within 6.4 years.
RESEARCH DESIGN AND METHODS— In a population-based cohort, the Hoorn
Study, plasma glucose was determined in 1989 and 1996 (n 1,428). Subjects were classified
in 1989 according to 1997 and 2003 ADA criteria. Subjects with IFG in 1989 were further
classified according to diabetes status in 1996. Hazard ratios for CVD mortality (n 81) in the
period 1996–2005 were adjusted for age and sex.
RESULTS— Subjects with IFG6.1, but not IFG5.6, had a significantly higher CVD mortality
risk than normal fasting glucose (NFG) subjects. Subjects who converted from IFG to diabetes
(IFG6.1: 42%; IFG5.6: 21%) had a more than twofold risk of CVD mortality (IFG6.1: 2.47
[1.17–5.19]; IFG5.6: 2.14 [1.12–4.10]) than subjects with NFG. IFG subjects who did not
develop diabetes did not have significantly higher CVD mortality risks (IFG6.1: 1.50 [0.72–
3.15]; IFG5.6: 1.15 [0.69–1.93]).
CONCLUSIONS— The lower cutoff for IFG (ADA 2003 criteria) results in a category of IFG
that no longer represents a high-risk state of CVD. Furthermore, only subjects who convert from
IFG to diabetes have a high risk of CVD mortality.
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Impaired glucose regulation is a high-risk state for type 2 diabetes and car-diovascular disease (CVD) (1).
Impaired glucose regulation can be either
impaired fasting glucose (IFG) or im-
paired glucose tolerance (IGT), i.e., ele-
vated glucose levels 2 h after the 75-g oral
glucose tolerance test (OGTT). Both con-
ditions contribute independently to the
high risk of diabetes and CVD but show
limited agreement (2,3). When the Amer-
ican Diabetes Association (ADA) intro-
duced fasting diagnostic criteria in 1997
to avoid the OGTT (4), which is not com-
monly used in clinical practice, the cutoff
for IFG was set at 6.1 mmol/l (IFG6.1). In
2003, the ADA decided that this value
should be lowered from 6.1 to 5.6 mmol/l
(IFG5.6) (5). This new cutoff for the def-
inition of IFG was selected as the level of
fasting glucose with the optimal sensitiv-
ity and specificity to predict incident dia-
betes in four population studies,
including the Hoorn Study. However, the
consequences of lowering the fasting glu-
cose cutoff in the definition of IFG for the
risk of CVD were not evaluated. Because
prevention programs at present are tar-
geted at impaired glucose regulation to
avoid both diabetes as well as CVD, this
point needs to be addressed. Thus, does
IFG confer a high-risk state of CVD, even
in individuals who do not develop diabe-
tes at a later stage? For IGT, it has been
shown that the elevated CVD risk was also
present in subjects who remained IGT or
returned to normal glucose tolerance (6).
Such information is not yet available for
subjects with IFG.
The aims of the present study were 1)
to assess the impact of lowering the IFG
cutoff on the prevalence of IFG and the
incidence of diabetes among subjects
classified as IFG in 1989, 2) to assess the
impact of lowering the IFG cutoff on the
associated risk of all-cause and CVD mor-
tality, and 3) to study if the association
between IFG and the risk of all-cause and
CVD mortality is independent of the con-
version to diabetes during follow-up.
RESEARCH DESIGN AND
METHODS
Study population
The Hoorn Study is a population-based
cohort study of glucose intolerance in a
general Dutch population, which started
in 1989. The study design has been de-
scribed in detail elsewhere (7). The study
cohort consisted of 2,484 Caucasian men
and women in 1989. A follow-up exami-
nation was performed between January
1996 and December 1998 (mean fol-
low-up duration was 6.4 years). Of the
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initial cohort, 150 subjects had died and
108 subjects had moved out of Hoorn. A
total of 140 other subjects were not in-
vited because of logistic reasons. Of the
remaining 2,086 subjects, 1,513 partici-
pated in the follow-up study in 1996. De-
tails of this follow-up study have been
described previously (3). All subjects
have been followed with respect to mor-
tality. The study was approved by the Eth-
ics Committee of the VU University
Medical Center. Informed consent was
obtained from all participants.
Glucose intolerance classification
Both in 1989 and 1996, a 75-g OGTT was
administered after an overnight fast. Fast-
ing plasma glucose (FPG) and 2-h post-
load plasma glucose levels were
determined with a glucose dehydroge-
nase method (Merck, Darmstadt, Ger-
many) in 1989 and with the hexokinase
method (Boehringer Mannheim, Mann-
heim, Germany) in 1996. Subjects (n 
41) who had already been using insulin,
blood glucose–lowering agents, or a diet
for diabetes were marked as “known dia-
betes mellitus” and were excluded from
the analyses. Furthermore, 44 subjects
were excluded because of missing infor-
mation of plasma glucose values. There-
fore, the analyses in the present study
were performed on 1,428 subjects who
completed both the measurements in
1989 and 1996. The prevalence of IFG
according to both the 1997 ADA criteria
(IFG6.1: IFG with FPG 6.1–7.0 mmol/l)
and 2003 ADA criteria (IFG5.6: IFG with
FPG 5.6–7.0 mmol/l) was determined for
1989 and 1996. Furthermore, all subjects
were classified with 1997 and 2003 ADA
criteria as normal fasting glucose (NFG),
impaired fasting glucose (IFG), or newly
discovered diabetes according to their
glucose status in 1989. For each set of
criteria, for subjects with IFG status in
1989, we distinguished between individ-
uals who had and who had not converted
to diabetes at the follow-up examination
in 1996–1998. For a timeline of the de-
sign of the present study, see Fig. 1.
Measurements
Weight and height were measured with
subjects wearing underwear only. BMI
was calculated as the ratio of weight and
squared height. Waist and hip circumfer-
ences were measured according to a stan-
dardized procedure (8). Waist-to-hip
ratio was defined as waist circumference
divided by hip circumference. Triglycer-
ides, total cholesterol, and HDL choles-
terol were determined from fasting blood
samples by enzymatic techniques (Boehr-
inger Mannheim). The Friedewald for-
mula was used to calculate the level of
LDL cholesterol (9).
Follow-up of mortality
There is a continuous registration of the
mortality of participants of the Hoorn
Study performed in cooperation with the
municipal registry of the city of Hoorn.
Information about causes of death was ex-
tracted from medical records of general
practitioners and the local hospital.
Causes of death were coded according to
the ICD-9 (10). Cardiovascular mortality
was defined as ICD-9 codes 390 – 459
(diseases of the circulatory system) or 798
(sudden death, cause unknown), because
sudden death is generally caused by CVD
(11). The vital status of subjects who had
moved out of Hoorn was obtained from
the municipal registries of the cities to
which they had moved. Follow-up data of
the period from the physical examination
in 1996 until 1 January 2005 were used to
calculate CVD mortality risks (Fig. 1).
Statistical analysis
Relative risks of all-cause and CVD mor-
tality during the period after the physical
examination in 1996 were estimated by
Cox proportional hazards analyses. For
both 1997 and 2003 ADA diagnostic cri-
teria, hazard ratios and 95% CIs for all-
cause and CVD mortality were obtained
for subjects with IFG status or diabetes
relative to those with NFG status. Because
this is a descriptive study, all models were
adjusted for age and sex only. Values are
presented as means SD. Statistical anal-
yses were performed using standard soft-
ware (SPSS 12.0.2). P values0.05 were
considered significant.
RESULTS— The characteristics of the
population classified according to both
1997 and 2003 ADA criteria in 1989 are
shown in Table 1. Subjects with IFG5.6
had a healthier profile than subjects with
IFG6.1 (e.g., lower blood pressure and
waist circumference). The prevalence of
IFG5.6 was 33.2% (95% CI 30.8–35.6)
and 10.1% (8.6–11.6) for IFG6.1. The
mean FPG level of the study population
was 5.6 1.3 mmol/l in 1989 and, after a
mean follow-up of 6.4 years, had in-
creased to 6.2 1.3 mmol/l in 1996. As a
result, the prevalence of IFG5.6 increased
to 55.7% (95% CI 53.2–58.2) and 25.6%
(23.4–27.8) for IFG6.1.
Of the subjects with IFG6.1 in 1989,
42% had progressed to diabetes (Table 2)
and the incidence rate was 66.5/1,000
person-years (95% CI 49.9–83.0). Of the
IFG5.6 subjects, only 21% developed di-
abetes (Table 2), with an incidence rate
32.7/1,000 person-years (26.3–39.1).
In the period from the physical exam-
ination in 1996 until 1 January 2005, 192
subjects died. For 184 of the deceased
(95.8%), the cause of death could be re-
trieved; 81 subjects died from CVD. Age-
and sex-adjusted hazard ratios for
all-cause and CVD mortality are shown in
Table 3. The hazard ratio of CVD mortal-
ity for subjects with IFG6.1 was 1.87
(1.07–3.25) relative to the reference cate-
gory with normal glucose levels (NFG).
The hazard ratio for CVD mortality for the
IFG5.6 group was lower and not statisti-
cally significant: 1.37 (0.87–2.16). The
associations with all-cause mortality
showed similar trends for both criteria:
the all-cause and CVD mortality risks for
subjects classified as IFG were both sig-
nificantly higher than for NFG subjects
and similar to the risks for newly detected
diabetic subjects.
Figure 1—Timeline of the study design. Subjects performed a first OGTT in 1989 and a second in
1996. The prevalence of IFG5.6 and IFG6.1 was obtained both in 1989 and 1996. Subjects were
classified according the 1997 and 2003 ADA criteria based on their first OGTT. Subjects with
IFG5.6 or IFG6.1 in 1989 were classified again in 1996 to determine whether they had converted
to diabetes or not. Follow-up data of cardiovascular mortality were used from 1996 until 2005.
DM, diabetes.
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When comparing subjects with IFG
status in 1989 who did and who did not
convert to diabetes in 1996, Cox regres-
sion revealed that the risks for all-cause
and CVD mortality were not significantly
higher than for NFG for subjects who had
not converted to diabetes (Table 3). Sub-
jects with IFG5.6 or IFG6.1 status who
had converted to diabetes during the 6.4
years of follow-up had higher all-cause
and CVD mortality risks than subjects
who were classified as newly discovered
diabetes in 1989 and had significantly (up
to 2.5 times) higher all-cause and CVD
mortality risks than subjects with normal
glucose status at that time.
CONCLUSIONS— The pre s en t
study showed that lowering the cutoff for
IFG from 6.1 to 5.6 mmol/l increases the
prevalence of IFG and reduces the inci-
dence rate of diabetes. Furthermore, the
hazard ratios of all-cause and cardiovas-
cular mortality were lower for IFG5.6
than for IFG6.1. In addition, the associa-
tion between IFG and the risk of all-cause
and CVD mortality is only present in sub-
jects who had converted to diabetes dur-
ing follow-up.
Limitations of the study
A number of possible study limitations
needs to be discussed. In this study, we
used a subpopulation of the Hoorn Study.
The baseline cohort of the Hoorn Study in
1989 was a random sample of the popu-
lation of the municipality of Hoorn, aged
50–70 years. For both the examinations
in 1989 and 1996, 70% response was
reached; this high rate of participation
suggests good representativeness. In pop-
ulation studies, however, generally,
participants are healthier than nonpartic-
ipants. Therefore, both the prevalence
and the incidence of diabetes might be
somewhat underestimated. A limitation
of the present study is the small number
of cases in the subgroups, thus limiting
the power of our study. However, the
large difference in the estimates of those
who did and those who did not convert,
along with the CIs, show a very clear pic-
ture. Furthermore, conclusions about
conversion to diabetes and about mortal-
ity were based only on those subjects who
survived the 6.4 years between the first
(1989) and second (1996) physical exam-
ination. Thus, numbers of conversion and
mortality may have been slightly higher.
However, this is one of very few popula-
tion studies with repeated glucose testing
(after 6.4 years) and subsequently 10
years of follow-up of mortality.
Consequences of lowering the IFG
cutoff for the prevalence of IFG and
incidence rate of diabetes
We found a considerably higher preva-
lence of IFG5.6 than IFG6.1. Similar
results have also been described by
Borch-Johnsen et al. (12) and Davidson et
al. (13), with IFG ranging from 24.1 to
38.8%. One of the reasons for proposing
the 2003 ADA criteria was to increase sen-
sitivity for the prediction of future diabe-
tes. However, this is at the cost of
specificity (5). According to our analyses,
the fraction of IFG5.6 subjects developing
diabetes decreased from 40 to 20% com-
pared with IFG6.1. Vaccaro and Riccardi
(14) studied the risk of progression from
IFG to diabetes in the Italian Telephone
Company (with a lower mean age than in
our study) and found an even lower per-
centage of 12.5% when subjects were
classified by 2003 ADA criteria. Thus,
with the new criteria, the prevalence of
IFG is increased considerably, while this
is accompanied by a lower risk of future
diabetes.
Table 1—Characteristics of the population classified according to both 1997 and 2003 ADA criteria in 1989
1997 ADA criteria 2003 ADA criteria Both criteria
NFG IFG NFG IFG
Type 2
diabetes
n 1,217 149 878 488 62
Age (years) 60.1  6.8 62.5  6.9 59.8  6.9 61.5  6.8 63.3  6.9
Sex (% male) 44.5 54.4 41.6 52.7 54.8
Height (cm) 169.1  8.6 169.1  8.6 168.8  8.7 169.6  8.6 169.1  9.3
Weight (kg) 74.7  10.7 78.9  11.2 73.7  10.5 77.8  10.9 82.3  13.8
BMI (kg/m2) 26.1  3.1 27.6  3.6 25.8  3.0 27.0  3.3 28.8  4.0
Cholesterol (mmol/l) 6.6  1.1 6.7  1.1 6.5  1.1 6.7  1.1 6.6  1.5
HDL cholesterol (mmol/l) 1.36  0.37 1.30  0.34 1.38  0.37 1.30  0.36 1.17  0.30
LDL cholesterol (mmol/l) 4.6  1.0 4.6  1.1 4.5  1.0 4.7  1.0 4.5  1.3
Triglycerides (mmol/l) 1.5  0.8 1.7  0.8 1.4  0.7 1.7  1.0 2.1  1.0
Hip circumference (cm) 101.5  6.2 102.8  7.1 101.2  6.01 102.4  6.7 104.4  7.1
Waist circumference (cm) 89.0  10.0 95.2  10.7 87.7  9.8 93.2  10.0 98.4  11.1
Waist-to-hip ratio 0.88  0.08 0.93  0.07 0.87  0.08 0.91  0.08 0.94  0.09
Diastolic blood pressure (mmHg) 81.4  10.1 84.9  9.7 80.6  9.9 83.8  10.2 85.5  11.8
Systolic blood pressure (mmHg) 131.4  19.2 144.5  19.6 129.5  18.2 138.9  20.7 143.4  17.3
Data are means  SD unless otherwise indicated. Type 2 diabetes represents newly discovered type 2 diabetes.
Table 2—A 6.4-year change in glucose tolerance status of subjects classified as IFG in 1989
1997 ADA criteria 2003 ADA criteria
Conversion to NFG 28 (18.8) 33 (6.8)
Remained IFG 59 (39.6) 354 (72.5)
Conversion to type 2 diabetes 62 (41.6) 101 (20.7)
Total 149 (100) 488 (100)
Data are n (%).
Fasting glucose and cardiovascular mortality
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Consequences of lowering the IFG
cutoff for CVD risk
Several studies have shown that IGT is a
risk factor for CVD mortality (6,15,16),
but there is debate whether this is also
true for IFG (17). Qiao et al. (6) reported
that IGT is a risk predictor for CVD mor-
bidity and mortality and for all-cause
mortality independent of the develop-
ment of overt diabetes. We and others
have previously shown that high 2-h glu-
cose after an OGTT is more closely asso-
ciated with an adverse CVD risk profile
and CVD risk (2,18). In the present study,
we showed that optimizing the cutoff of
IFG for identification of future diabetes
does not correspond to the risk of all-
cause and CVD mortality and that the
CVD mortality risk of IFG subjects is only
present in those who convert to diabetes.
Subjects with IFG5.6 at baseline who had
diabetes at follow-up had significantly
lower HDL cholesterol and higher triglyc-
erides, waist circumference, waist-to-hip
ratio, and systolic blood pressure than
subjects who did not have diabetes at fol-
low-up (data not shown), indicating large
differences in CVD risk profile between
subjects who do and do not convert to
diabetes. In subjects with IFG6.1, differ-
ences were smaller and only statistically
significant for triglycerides levels (data
not shown), indicating a more homoge-
neous group of IFG subjects with less rel-
atively healthy subjects included.
We previously reported lower CVD
mortality risk in subjects with FPG be-
tween 5.6 and 6.0 mmol/l (18). Now,
with an even longer follow-up duration,
we find that CVD mortality risk in the
IFG5.6 group is not significantly higher
than NFG subjects. Balkau et al. (19) re-
ported J-shaped relationships with fasting
glucose concentrations and all-cause
mortality in men in the Paris Prospective
Study, with a lowest mortality around
FPG levels of 5.5 mmol/l. The DECODE
(Diabetes Epidemiology: Collaborative
analysis of Diagnostic criteria in Europe)
study group also found that the 7-year
risk of coronary heart disease was lower in
women with a fasting glucose value be-
tween 5.6 and 6.0 mmol/l compared with
women with NFG (20). Because of such
findings, the lower cutoff of the 2003
ADA criteria for IFG has been questioned
(21,22). This reported J-shape and the re-
sults of the present study are strong rea-
sons to reconsider the recommendation
to lower the IFG cutoff to 5.6 mmol/l.
Consequences of lowering the IFG
cutoff for early prediction of CVD
and diabetes
The high incidence of type 2 diabetes in
recent years has led to focus on the possi-
bilities of prevention of diabetes. Indeed,
lifestyle intervention studies have con-
vincingly shown that in subjects with
IGT, risk of diabetes and development of
abnormal levels of cardiovascular risk fac-
tors could be reduced (23–25). However,
the IFG5.6 group includes a very large,
relatively healthy group of subjects with a
different metabolic profile than IGT sub-
jects. It is questionable if prevention strat-
egies would be similarly effective in IFG
as in IGT subjects with high risk of devel-
oping diabetes. In the present study, one-
third of the population would be
classified as IFG5.6, while the risk of de-
veloping diabetes is lower and the CVD
mortality risk is similar to that of NFG
subjects. The fact that high CVD mortality
risk is only present in those subjects who
will develop diabetes within 6 years indi-
cates that our focus should lie on treat-
ment of CVD risk factors and early
detection of diabetes.
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